Multiple signalling pathways are enriched significantly in tumour samples with high NLRP1 expression, including allograft rejection, angiogenesis, apical junction, apoptosis, coagulation, complement activation, epithelial‐mesenchymal transition (EMT), IL‐2/STAT5 signalling, IL‐6/JAK/STAT3 signalling, inflammatory response, interferon‐alpha response, interferon‐gamma response, KRAS signalling, TNF‐alpha signalling via NF‐kB and the p53 pathway etc. (Figure 10). The gene discussed is KRAS; the disease is neoplasm.